Acurx Pharmaceuticals: reports results of annual meeting votes

What happened Acurx Pharmaceuticals reported in a Form 8-K filed Oct 16, 2026 that at its annual meeting held Oct 16, 2026 stockholders elected two Class II directors and ratified the appointment of CohnReznick LLP as its independent registered public accounting firm. At the close of business on Aug 20, 2026 (the record date) there were 5,471,297 shares of common stock outstanding. Stockholders representing 2,890,899 shares, or 52.83% of outstanding shares, were present in person or by proxy.

Key details

• Class II directors elected to three-year terms expiring in 2029: David P. Luci (For 1,187,323; Withheld 73,804; Broker non-votes 1,629,772) and Jack H. Dean (For 1,203,310; Withheld 57,817; Broker non-votes 1,629,772).
• Ratification of independent registered public accounting firm: CohnReznick LLP was ratified (For 2,877,193; Against 8,473; Abstentions 5,233; Broker non-votes N/A).

Why it may matter This filing is Item 5.07 (Submission of Matters to a Vote of Security Holders) and reports the voting outcomes on director elections and auditor ratification at the Oct 16, 2026 annual meeting. The filing does not show why the insider traded or why the company acted.